Volume 11, Issue 2 (6-2023)                   JoMMID 2023, 11(2): 62-70 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rukasha I, Lekalakala-Mokaba M R, Satekge T, Kaapu K G. Seroprevalence of SARS-CoV-2 IgG and IgM in Diabetic and Oncology patients at Pietersburg Hospital, Limpopo, South Africa. JoMMID 2023; 11 (2) :62-70
URL: http://jommid.pasteur.ac.ir/article-1-527-en.html
Division of Medical Microbiology, Department of Pathology, School of Medicine, University of Limpopo, Sovenga, Limpopo Province, South Africa
Abstract:   (1011 Views)
Introduction: The global COVID-19 pandemic has disproportionately impacted people with weakened immune systems. Non-communicable diseases, which include diabetes and cancer, are the top causes of weakened immune systems, recording up to 74% of all deaths globally. Studying the seroprevalence is crucial in understanding the epidemiology of the virus and contributes to the improved management of COVID-19 amongst patients with cancer and diabetes. Methods: The study was a single-center prospective study that tested serum samples for routine chemical analysis from March to July 2022 at NHLS, Chemical Pathology, Polokwane laboratory using the COVID-19 IgG/IgM Rapid Test Cassette - Orient Gene Biotech, Zhejiang, China. The assay tests antibodies against SARS-CoV-2 in the early (lgM) and later stage (lgG) of infection. Results: Of the 207 patients with diabetes, 84% had detectable IgG and IgM antibodies against SARS-CoV-2. Similarly, 81% of the 283 cancer patients had detectable IgG and IgM antibodies against SARS-CoV-2. The patients with diabetes had a median age of 56 years (range: 0-91), and 60% were females. The cancer patients had a median age of 62 years (range: 49-72), and 40% were females. Conclusion: The study demonstrates a high SARS-CoV-2 IgG and IgM antibody seroprevalence in diabetic and oncology patients at Pietersburg Hospital, Limpopo, South Africa. These findings emphasize the importance of ongoing serologic testing to track the pandemic, particularly among immunocompromised patients, and inform the development of effective public health strategies to mitigate COVID-19 transmission.
Full-Text [PDF 1108 kb]   (503 Downloads)    
Type of Study: Original article | Subject: Diagnostic/screening methods and protocols
Received: 2023/02/8 | Accepted: 2023/06/11 | Published: 2023/07/18

References
1. Dai Y-C, Lin Y-C, Ching LL, Tseng AC, Qin Y, Nerurkar VR, et al. Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave. Front Med. 2022; 9: 3534. [DOI:10.3389/fmed.2022.1019490] [PMID] [PMCID]
2. COVID Live - Coronavirus Statistics - Worldometer, https://www.worldometers.info/coronavirus/ (accessed 18 April 2022).
3. WHO. Noncommunicable diseases. 2022, https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases (2022, accessed 6 December 2022).
4. WHO. South Africa cancer statistics 2020. International Agency on Cancer, https://gco.iarc.fr/today/data/factsheets/populations/710-south-africa-fact-sheets.pdf (2020, accessed 19 April 2022).
5. The Centre for Diabetes and Endocrinology. Diabetes in South Africa: Assessing the Data with Fear and Trembling. 2016; 2015: 1-3.
6. Nicholson CJ, Wooster L, Sigurslid HH, Li RH, Jiang W, Tian W, et al. Estimating risk of mechanical ventilation and in-hospital mortality among adult COVID-19 patients admitted to Mass General Brigham: The VICE and DICE scores. EClinicalMedicine. 2021; 33: 100765. [DOI:10.1016/j.eclinm.2021.100765] [PMID] [PMCID]
7. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020; 10 (6): 783-91. [DOI:10.1158/2159-8290.CD-20-0422] [PMID] [PMCID]
8. Lima A, Sousa H, Nobre A, Faria AL, Machado M. The Impact of COVID-19 Pandemic in Portuguese Cancer Patients: A Retrospective Study. Int J Environ Res Public Health. 2021; 18 (16): 8552. [DOI:10.3390/ijerph18168552] [PMID] [PMCID]
9. Rolfo C, Cardona AF, Ruiz-Patiño A, Ariza S, Zatarain-Barron L, Pino LE, et al. Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019-Infected Patients With Lung Cancer. J Thorac Oncol. 2020; 15 (11): 1767-72. [DOI:10.1016/j.jtho.2020.06.019] [PMID] [PMCID]
10. Harvey RA, Rassen JA, Kabelac CA, Turenne W, Leonard S, Klesh R, et al. Association of SARS-CoV-2 Seropositive Antibody Test with Risk of Future Infection. JAMA Intern Med. 2021; 181 (5): 672-9. [DOI:10.1001/jamainternmed.2021.0366] [PMID] [PMCID]
11. Fuereder T, Berghoff AS, Heller G, Haslacher H, Perkmann T, Strassl R, et al. SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic. ESMO open. 2020; 5 (5): e000889. [DOI:10.1136/esmoopen-2020-000889] [PMID] [PMCID]
12. Cabezón-Gutiérrez L, Custodio-Cabello S, Palka-Kotlowska M, Oliveros-Acebes E, García-Navarro MJ, Khosravi-Shahi P. Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data. Cancer Treat Rev. 2020; 90: 102102. [DOI:10.1016/j.ctrv.2020.102102] [PMID] [PMCID]
13. Overheu O, Quast DR, Schmidt WE, Sakinç-Güler T, Reinacher-Schick A. Low Serological Prevalence of SARS-CoV-2 Antibodies in Cancer Patients at a German University Oncology Center. Oncol Res Treat. 2022; 45 (3): 112-7. [DOI:10.1159/000520572] [PMID] [PMCID]
14. Madhi SA, Kwatra G, Myers JE, Jassat W, Dhar N, Mukendi CK, et al. Population Immunity and Covid-19 Severity with Omicron Variant in South Africa. N Engl J Med. 2022; 386 (14): 1314-26. [DOI:10.1056/NEJMoa2119658] [PMID] [PMCID]
15. Mutevedzi PC, Kawonga M, Kwatra G, Moultrie A, Baillie VL, Mabhena N, et al. Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey. Int J Epidemiol. 2022; 51 (2): 404-17. [DOI:10.1093/ije/dyab217] [PMID] [PMCID]
16. Lewis H, Ware H, Whelan M, Subissi L, Li Z, Ma X, et al. SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. BMJ Glob Health. 2022; 7 (8): e008793 [DOI:10.1136/bmjgh-2022-008793] [PMID] [PMCID]
17. Zambelli A, Fotia V, Bosetti T, Negrini G, di Croce A, Moro C, et al. 1676MO Prevalence and clinical impact of asymptomatic or mildly symptomatic SARSCoV-2 infection among actively treated cancer patients during COVID-19 pandemic in Italy. Ann Oncol. 2020; 31: S994. [DOI:10.1016/j.annonc.2020.08.1741] [PMCID]
18. Cantini L, Bastianelli L, Lupi A, Pinterpe G, Pecci F, Belletti G, et al. Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy. J Clin Med. 2021; 10 (7):1503. [DOI:10.3390/jcm10071503] [PMID] [PMCID]
19. Goyal A, Gupta Y, Kalaivani M, Praveen PA, Ambekar S, Tandon N. SARS-CoV-2 Seroprevalence in Individuals With Type 1 and Type 2 Diabetes Compared With Controls. Endocr Pract. 2022; 28 (2): 191-8. [DOI:10.1016/j.eprac.2021.12.009] [PMID] [PMCID]
20. Peykari N, Eybpoosh S, Safikhani H, Haghdoost AA, Tabatabaei-Malazy O, Larijani B. Non-communicable Diseases and COVID-19; a double-edged sword A Special Communication from IRAN. J Diabetes Metab Disord. 2020; 19 (2): 2057-61. [DOI:10.1007/s40200-020-00683-1] [PMID] [PMCID]
21. Singh RP, Javaid M, Haleem A, Suman R. Internet of things (IoT) applications to fight against COVID-19 pandemic. Diabetes Metab Syndr Clin Res Rev. 2020; 14 (4): 521-4. [DOI:10.1016/j.dsx.2020.04.041] [PMID] [PMCID]
22. Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? Front Physiol. 2021; 11: 571416. [DOI:10.3389/fphys.2020.571416] [PMID] [PMCID]
23. Alves AS, Bueno V. Immunosenescence: participation of T lymphocytes and myeloid-derived suppressor cells in aging-related immune response changes. Einstein (Sao Paulo). 2019; 17 (2): eRB4733. [DOI:10.31744/einstein_journal/2019RB4733] [PMID] [PMCID]
24. WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19), https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19) (2020, accessed 24 January 2023).
25. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020; 323 (18): 1775-6. [DOI:10.1001/jama.2020.4683] [PMID]
26. Ngwewondo A, Nkengazong L, Ambe LA, Ebogo JT, Mba FM, Goni HO, et al. Knowledge, attitudes, practices of/towards COVID 19 preventive measures and symptoms: A cross-sectional study during the exponential rise of the outbreak in Cameroon. PLoS Negl Trop Dis. 2020; 14 (9): e0008700. [DOI:10.1371/journal.pntd.0008700] [PMID] [PMCID]
27. Chitungo I, Dzobo M, Hlongwa M, Dzinamarira T. COVID-19: Unpacking the low number of cases in Africa. Public Heal Pract. 2020; 1: 100038. [DOI:10.1016/j.puhip.2020.100038] [PMID] [PMCID]
28. Álvarez-Antonio C, Meza-Sánchez G, Calampa C, Casanova W, Carey C, Alava F, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study. Lancet Glob Heal. 2021; 9 (7): e925-e31. [DOI:10.1016/S2214-109X(21)00173-X] [PMID]
29. Adam MH, Mohamoud JH, Mohamood AS, Mohamed AA, Garba B, Dirie NI. Seroprevalence of Anti-SARS-CoV-2 Antibodies in Benadir Region, Somalia. Vaccines. 2022; 10 (2): 220. [DOI:10.3390/vaccines10020220] [PMID] [PMCID]
30. WHO. True extent of SARS-CoV-2 Infection through seroprevalence studies, https://www.who.int/news/item/03-02-2022-true-extent-of-sars-cov-2-infection-through-seroprevalence-studies (2022, accessed 27 November 2022).
31. Chakravarty D, Ratnani P, Sobotka S, Lundon D, Wiklund P, Nair SS, et al. Increased hospitalization and mortality from covid-19 in prostate cancer patients. Cancers (Basel). 2021; 13 (7): 1630. [DOI:10.3390/cancers13071630] [PMID] [PMCID]
32. Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunol. 2020; 9 (5): e1136. [DOI:10.1002/cti2.1136] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.